Wednesday, August 17, 2022 10:44:37 AM
FeMike,
You are correct but.. they would only get the license based on the need to have one for commercial scale production of some product. If that product was for anything other than DCVax-L initially, NWBO/Linda would be in serious trouble since Sawston, unlike Cognate, did not significantly contribute to the trial process to benefit NWBO shareholders and Specials certification is a lesser cert. Sawston must be certified based on DCVax-L commercializtion or the blowback on Linda/Toucan would have teeth. They won’t go there without serious repercussions hence they won’t go there. Therefore, speculation that Sawston would be approved commercially without a focus on L is speculation without any serious merit. Best wishes.
You are correct but.. they would only get the license based on the need to have one for commercial scale production of some product. If that product was for anything other than DCVax-L initially, NWBO/Linda would be in serious trouble since Sawston, unlike Cognate, did not significantly contribute to the trial process to benefit NWBO shareholders and Specials certification is a lesser cert. Sawston must be certified based on DCVax-L commercializtion or the blowback on Linda/Toucan would have teeth. They won’t go there without serious repercussions hence they won’t go there. Therefore, speculation that Sawston would be approved commercially without a focus on L is speculation without any serious merit. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
